Roger Paredes

Current evidence on islatravir drug resistance and implications for future HIV treatment.

Journal: Topics in antiviral medicine

Published: July 17, 2026

Andes hantavirus: operationalising science in real time.

Journal: Lancet (London, England)

Published: June 05, 2026

Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios.

Journal: Viruses

Published: April 23, 2026

Airway organoids reveal patterns of influenza A tropism and adaptation in wildlife species.

Journal: Emerging microbes & infections

Published: April 17, 2026

Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.

Journal: The Journal of infectious diseases

Published: April 12, 2026

Cardiovascular Disease Risk with Integrase Inhibitor-based Antiretroviral Therapy: A Causal Inference Analysis in RESPOND.

Journal: Open forum infectious diseases

Published: March 19, 2026

Blinded two-year longitudinal evaluation of SARS-CoV-2 antigenemia in long COVID.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: February 16, 2026

Blinded 2-Year Longitudinal Evaluation of SARS-CoV-2 Antigenemia in Long COVID.

Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Published: February 16, 2026

Retrospective Analysis of the Epidemiology and Risk Factors for Recurrent Biliary-Source Bloodstream Infections in Oncologic Patients.

Journal: Antibiotics (Basel, Switzerland)

Published: February 07, 2026

Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: January 21, 2026

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Journal: The lancet. HIV

Published: January 12, 2026

Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research.

Journal: The Journal of infectious diseases

Published: December 23, 2025

Current evidence on islatravir drug resistance and implications for future HIV treatment.

Current evidence on islatravir drug resistance and implications for future HIV treatment.

Andes hantavirus: operationalising science in real time.

Andes hantavirus: operationalising science in real time.

Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios.

Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined Scenarios.

Airway organoids reveal patterns of influenza A tropism and adaptation in wildlife species.

Airway organoids reveal patterns of influenza A tropism and adaptation in wildlife species.

Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.

Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.

Cardiovascular Disease Risk with Integrase Inhibitor-based Antiretroviral Therapy: A Causal Inference Analysis in RESPOND.

Cardiovascular Disease Risk with Integrase Inhibitor-based Antiretroviral Therapy: A Causal Inference Analysis in RESPOND.

Blinded two-year longitudinal evaluation of SARS-CoV-2 antigenemia in long COVID.

Blinded two-year longitudinal evaluation of SARS-CoV-2 antigenemia in long COVID.

Blinded 2-Year Longitudinal Evaluation of SARS-CoV-2 Antigenemia in Long COVID.

Blinded 2-Year Longitudinal Evaluation of SARS-CoV-2 Antigenemia in Long COVID.

Retrospective Analysis of the Epidemiology and Risk Factors for Recurrent Biliary-Source Bloodstream Infections in Oncologic Patients.

Retrospective Analysis of the Epidemiology and Risk Factors for Recurrent Biliary-Source Bloodstream Infections in Oncologic Patients.

Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial.

Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial.

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research.

Implementation Does Not Occur in a Vacuum: Sustaining a Comprehensive and Global Vision for HIV Research.

Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.

Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.